Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

PURPOSE: Efficacy and safety of agalsidase alfa at 0.2 mg/kg weekly were compared with 0.2 mg/kg every other week (EOW). Exploratory analyses were performed for 0.4 mg/kg weekly. PATIENTS AND METHODS: This was a 53-week, Phase III/IV, multicenter, open-label study (NCT01124643) in treatment-naïve ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Goláň, Lubor, Goker-Alpan, Ozlem, Holida, Myrl, Kantola, Ikka, Klopotowski, Mariusz, Kuusisto, Johanna, Linhart, Aleš, Musial, Jacek, Nicholls, Kathleen, Gonzalez-Rodriguez, Derlis, Sharma, Reena, Vujkovac, Bojan, Chang, Peter, Wijatyk, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501226/
https://www.ncbi.nlm.nih.gov/pubmed/26185417
http://dx.doi.org/10.2147/DDDT.S80928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501226/
https://www.ncbi.nlm.nih.gov/pubmed/26185417
http://dx.doi.org/10.2147/DDDT.S80928

Ejemplares similares